Formulation and evaluation of Itraconazole nanoemulsion for enhanced oral bioavailability

Journal of Microencapsulation
Hetal ThakkarArpita A Patel

Abstract

Itraconazole (ITR), an antifungal agent has poor bioavailability due to low aqueous solubility. The present investigation aimed at development of ITR nanoemulsion to enhance its oral bioavailability. ITR nanoemulsion was prepared using Capmul MCM C8 as oil, Pluronic F68 as co-surfactant and Cremophore EL as surfactant using high speed stirring, followed by probe sonication. Nanoemulsion with average globule size of 100.9 nm and zeta potential of -35.9 ± 1.2 mV was able to penetrate well into the intestinal membrane as confirmed by the laser confocal scanning microscopy and ex vivo intestinal permeability study. Antimycotic study confirmed the efficacy of ITR nanoemulsion. Significantly higher values of pharmacokinetic parameters the formulation than the plain drug and marketed formulation indicated an increase in the bioavailability of ITR. The prepared nanoemulsion was stable at both, refrigerated and room temperature conditions. Nanoemulsion of ITR seems to be a promising formulation for enhancement of its oral bioavailability.

References

Jan 1, 1988·Antimicrobial Agents and Chemotherapy·M S Saag, W E Dismukes
Sep 30, 1999·International Journal of Pharmaceutics·J Y JungK H Lee
Feb 24, 2001·Drugs·K De Beule, J Van Gestel
Aug 31, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H GelderblomA Sparreboom
Oct 20, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·N Singh
Jan 14, 2003·Pharmaceutical Research·Norbert Rasenack, Bernd W Müller
Mar 23, 2004·Pharmaceutical Research·Robert G Strickley
Apr 28, 2004·Drug Development and Industrial Pharmacy·Jiahui HuRobert O Williams
Jul 22, 2004·International Journal of Pharmaceutics·K BouchemalH Fessi
Aug 13, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hilmar WisplinghoffMichael B Edmond
Nov 22, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Ji-Yeon HongChong-Kook Kim
Jan 8, 2008·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Jong Soo WooChong-Kook Kim
Feb 1, 1996·International Journal of Antimicrobial Agents·K De Beule
Mar 12, 2009·AAPS PharmSciTech·Ghada Abdelbary, Rania H Fahmy
Mar 9, 2010·Drug Discovery Today·Huabing ChenJinming Gao
Dec 1, 2011·Critical Care : the Official Journal of the Critical Care Forum·Hannah MuskettDavid Harrison
Apr 6, 2012·Annual Review of Physical Chemistry·Michael M Fryd, Thomas G Mason
Apr 20, 2012·Expert Opinion on Drug Delivery·Sabna KottaJaved Ali
May 12, 2012·Mycoses·F Fernández-CamposA C Calpena Campmany
Nov 24, 2012·Journal of Pharmaceutical Sciences·Ijeoma F Uchegbu, Adeline Siew

❮ Previous
Next ❯

Citations

Jun 24, 2017·Chemico-biological Interactions·Karolina NiskaIwona Inkielewicz-Stepniak
Oct 6, 2020·Frontiers in Cellular and Infection Microbiology·Brenda KischkelCarlos P Taborda

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.